{"id":1533,"date":"2016-11-15T12:20:43","date_gmt":"2016-11-15T12:20:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1533"},"modified":"2024-09-17T16:15:34","modified_gmt":"2024-09-17T10:45:34","slug":"notizia-14","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-14","title":{"rendered":"Aurobindo\u2019s net profit; LLS selects; Eli Lilly secures; DNA vaccine against Zika"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1294ecd549d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1294ecd549d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\/#Aurobindo_Pharma_Q2_net_profit_up_3353_to_Rs_606_cr\" >Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\/#The_Leukemia_Lymphoma_Society_LLS_Selects_INC_Research_for_AML_Master_Trial\" >The Leukemia &amp; Lymphoma Society (LLS) Selects INC Research for AML Master Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\/#Eli_Lilly_secures_conditional_marketing_authorisation_for_olaratumab_injection_with_doxorubicin\" >Eli Lilly secures conditional marketing authorisation for olaratumab injection with doxorubicin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\/#Study_reveals_synthetic_DNA_vaccine_approach_successfully_protects_against_Zika_virus\" >Study reveals synthetic DNA vaccine approach successfully protects against Zika virus<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Q2_net_profit_up_3353_to_Rs_606_cr\"><\/span><span style=\"color: #000080;\">Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of joint ventures of Rs 453.55 crore for the same period a year ago. Consolidated total income from operations also rose to Rs 3,775.45 crore for the quarter under consideration as against Rs 3,365.11 crore for the corresponding period of the previous fiscal.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"The_Leukemia_Lymphoma_Society_LLS_Selects_INC_Research_for_AML_Master_Trial\"><\/span><span style=\"color: #000080;\">The Leukemia &amp; Lymphoma Society (LLS) Selects INC Research for AML Master Trial<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The Beat AML Master Trial is the first time a non-profit is working with multiple pharma and biopharma sponsors and other key collaborators to operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML. Newly diagnosed AML patients will enter this study based on screening for specific molecular mutations known to be drivers of their disease, and will be matched to a specific targeted therapy.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Eli_Lilly_secures_conditional_marketing_authorisation_for_olaratumab_injection_with_doxorubicin\"><\/span><span style=\"color: #000080;\">Eli Lilly secures conditional marketing authorisation for olaratumab injection with doxorubicin<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The European Commission (EC) has granted conditional marketing authorization for Eli Lilly and Company\u2019s olaratumab injection of 10mg\/ml in combination with doxorubicin, to treat adults with advanced soft tissue sarcoma (STS) who are not suited for curative surgery or radiotherapy and were not previously treated with doxorubicin. Olaratumab is a recombinant, human immunoglobulin G subclass 1 (IgG1) monoclonal antibody. Data from the Phase II portion of the pivotal JGDG trial has paved the way for the conditional marketing authorization followed by a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Study_reveals_synthetic_DNA_vaccine_approach_successfully_protects_against_Zika_virus\"><\/span><span style=\"color: #000080;\">Study reveals synthetic DNA vaccine approach successfully protects against Zika virus<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">A new research has indicated that a synthetic DNA vaccine approach has been able to successfully protect against infection, brain damage and death caused by the mosquito-borne Zika virus in-vivo. There are currently no licensed therapies or vaccines to protect against the Zika virus. In this preclinical study conducted by the Wistar Institute, all of the animal models were protected after vaccination followed by a challenge with the Zika virus. In addition, they were protected from degeneration in the cerebral cortex and hippocampal areas of the brain, while the other cohort showed the brain&#8217;s degeneration after Zika infection.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma Q2 net profit up 33.53% to Rs. 606 cr Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust formulation sales. The company had posted a net profit after tax, minority interest and share of profit of joint [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1534,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[204,646,464,645],"industry":[17225],"therapeutic_areas":[17231,17228,17234],"class_list":["post-1533","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight","tag-doxorubicin","tag-pharma","tag-zika-virus","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Aurobindo Pharma and Eli Lilly<\/title>\n<meta name=\"description\" content=\"Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Aurobindo Pharma and Eli Lilly\" \/>\n<meta property=\"og:description\" content=\"Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-14\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-15T12:20:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:45:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"282\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Aurobindo Pharma and Eli Lilly","description":"Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-14","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Aurobindo Pharma and Eli Lilly","og_description":"Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-14","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-11-15T12:20:43+00:00","article_modified_time":"2024-09-17T10:45:34+00:00","og_image":[{"width":640,"height":282,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-14","url":"https:\/\/www.delveinsight.com\/blog\/notizia-14","name":"Pharma News | Aurobindo Pharma and Eli Lilly","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-14#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-14#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","datePublished":"2016-11-15T12:20:43+00:00","dateModified":"2024-09-17T10:45:34+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Aurobindo Pharma reported 33.53 per cent rise in consolidated net profit to Rs 605.64 crore for the quarter ending September mainly on account of robust...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-14"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-14#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","width":640,"height":282},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Doxorubicin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zika virus<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Doxorubicin<\/span>","<span class=\"advgb-post-tax-term\">Pharma<\/span>","<span class=\"advgb-post-tax-term\">Zika virus<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 15, 2016","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Nov 15, 2016 12:20 pm","modified":"Updated on Sep 17, 2024 4:15 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1533"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1533\/revisions"}],"predecessor-version":[{"id":29554,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1533\/revisions\/29554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1534"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1533"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1533"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}